activ
regul
cascad
system
blood
complement
system
coagulationcontact
activationkallikrein
system
fibrinolyt
system
occur
via
activ
zymogen
molecul
specif
activ
proteolyt
enzym
despit
fact
gener
proteas
present
togeth
blood
physiolog
condit
activ
gener
proteas
control
endogen
proteas
inhibitor
consequ
remark
littl
crosstalk
differ
system
fluid
phase
concept
review
articl
aim
identifi
describ
condit
strict
systemrel
control
circumv
includ
clinic
set
massiv
amount
proteolyt
enzym
releas
tissu
eg
pancreat
posttraumat
tissu
damag
result
consumpt
natur
substrat
specif
proteas
avail
proteas
inhibitor
anoth
exampl
cascad
system
dysregul
dissemin
intravascular
coagul
canon
activ
cascad
system
blood
also
lead
specif
substrat
proteas
inhibitor
elimin
present
review
explain
basic
concept
proteas
biochemistri
import
understand
clinic
condit
extens
proteas
activ
proteas
express
ubiquit
tissu
human
bodi
definit
word
bproteinaseder
greek
word
bprotelo
mean
bfirst
rank
combin
word
bdiastasi
mean
bcleavageor
bseparationproteas
capabl
cleav
bfirstrankmolecul
seem
excess
releas
activ
local
inflammatori
condit
result
local
barrier
breakdown
cellular
dysfunct
invas
inflammatori
cell
andor
microorgan
longstand
evid
proteas
involv
mani
acut
diseas
proteas
proteinas
peptidas
enzym
hydrolyz
peptid
bond
substrat
protein
found
live
organ
includ
plant
classifi
basi
catalyt
residu
activ
site
particular
enzym
beststudi
group
serin
proteas
cystein
proteas
aspart
proteas
metalloproteas
although
addit
group
also
defin
overal
reaction
mechan
proteasemedi
cleavag
involv
nucleophil
attack
target
peptid
bond
proteas
substrat
gener
nucleophil
involv
catalyt
triad
amino
acid
serin
cystein
proteas
histidin
residu
remov
proton
hydroxyl
thiol
serin
cystein
respect
aspart
proteas
metalloproteas
activ
water
molecul
articl
contribut
special
issu
complement
health
diseas
novel
aspect
insight
guest
editor
paul
morgan
david
kavanagh
perform
nucleophil
attack
metalloproteas
oblig
need
dival
metal
cation
activ
site
enzym
usual
zinc
case
also
cobalt
present
select
proteas
within
main
group
relev
scope
review
articl
within
serin
proteas
group
chymotrypsin
famili
includ
numer
proteas
within
complement
system
contact
activ
kallikrein
coagul
system
fibrinolyt
system
famili
also
includ
enzym
deriv
pancrea
elastas
endopeptidas
trypsin
chymotrypsin
leukocyteorigin
proteas
cathepsin
g
proteinas
leukocyt
elastas
variou
tryptas
granzym
relev
enzym
within
cystein
proteas
group
papain
cathepsin
b
h
k
l
calpain
within
aspart
proteas
group
pepsin
gastricsin
pepsinogen
c
renin
cathepsin
e
metalloproteas
group
includ
matrix
proteas
collagenas
gelatinas
involv
tissu
remodel
well
enzym
within
adamt
famili
addit
variou
carboxypeptidas
exopeptidas
belong
group
releas
plasma
desargin
reduc
activ
bradykinin
anaphylatoxin
summari
proteas
relev
review
articl
exampl
substrat
within
complement
system
given
tabl
specif
given
enzym
substrat
vari
greatli
promiscu
proteas
like
trypsin
recogn
singl
basic
amino
acid
arg
ly
substrat
consequ
abl
cleav
protein
contain
expos
either
two
amino
acid
like
trypsin
thrombin
also
cleav
substrat
carboxyl
side
arg
multipl
substrat
unlik
trypsin
cleav
protein
specif
posit
defin
kinet
elastas
usual
cleav
protein
carboxyltermin
side
amino
acid
small
uncharg
group
ala
gli
val
likelihood
proteas
cleav
given
protein
target
may
express
term
enzym
kinet
k
cat
k
catalyt
effici
enzym
enzym
follow
michaelismenten
kinet
v
max
maxim
veloc
satur
substrat
concentr
k
substrat
concentr
reaction
rate
half
v
max
k
cat
turnov
number
relat
v
max
concentr
activ
site
enzym
k
cat
k
use
measur
substrat
prefer
catalyt
effici
enzym
chymotrypsin
archetyp
serin
proteas
abl
cleav
protein
carboxyl
side
larg
hydrophob
aromat
amino
acid
substrat
prefer
demonstr
use
seri
substrat
increasingli
hydrophob
amino
acid
give
higher
higher
k
cat
k
valu
indic
effici
cleavag
obtain
aromat
amino
acid
phe
proteas
gener
blood
activ
plasma
cascad
system
complement
system
coagulationcontactkallikrein
system
fibrinolyt
system
case
lead
activ
zymogen
molecul
yield
activ
proteolyt
enzym
altern
proteas
may
releas
activ
leukocyt
andor
damag
tissu
invad
pathogen
sepsi
regardless
origin
proteas
present
blood
control
number
proteas
inhibitor
make
total
amount
plasma
protein
inhibitor
show
great
differ
specif
concentr
inhibitor
antithrombin
inhibit
recognit
proteas
classic
lectin
pathway
complement
proteas
activ
within
contact
system
factor
f
xiia
fxia
kallikrein
plasmin
also
inhibit
fviia
fixa
fxa
thrombin
within
coagul
system
addit
trypsin
serin
proteas
inhibitor
serpin
altern
design
inhibitor
inhibitor
mainli
inhibit
type
serin
proteas
ie
addit
gener
within
complement
coagul
system
cathepsin
g
chymotrypsin
plasmin
trypsin
differ
combin
also
collagenas
final
show
broadest
specif
inhibit
almost
proteas
class
includ
pathogen
origin
summari
target
specif
plasma
concentr
proteas
given
tabl
proteolyt
cleavag
key
complement
compon
complement
noncompl
proteas
complement
compon
proteas
cleav
physiolog
condit
split
protein
distinct
site
within
molecul
yield
characterist
fragment
fig
site
extent
share
noncompl
proteas
gener
activ
product
similar
physiolog
fragment
therefor
appropri
start
describ
physiolog
fragment
occur
activ
initi
proteolyt
cleavag
made
classicallectin
altern
pathway
convertas
respect
restrict
cleav
one
argser
bond
residu
produc
releas
larger
molecul
fig
next
three
physiolog
cleavag
mediat
serin
proteas
factor
factor
expos
catalyt
site
directli
upon
contact
order
cleavag
occur
absolut
requir
one
sever
cofactor
factor
h
plasma
membranebound
mcp
cleavag
site
locat
close
togeth
cub
domain
first
locat
posit
second
posit
argser
sequenc
whose
cleavag
produc
main
fragment
fig
third
major
cleavag
occur
posit
argglu
cleav
g
fragment
produc
larger
fragment
fig
addit
cleavag
lysglu
also
report
bind
interact
complement
receptor
bind
bind
g
anoth
ligand
differenti
bind
fragment
repres
regul
function
fragment
cell
lysi
cell
adher
cell
activ
phagocytosi
cytotox
etc
becom
transform
ligand
immunoregul
therebi
link
innat
adapt
immun
review
addit
physiolog
fragment
also
describ
first
identifi
leukocytosisinduc
peptid
although
origin
fragment
identifi
time
decad
identif
fragment
anoth
possibl
relat
fragment
identifi
glike
fragment
could
gener
cleavag
use
contact
system
proteas
kallikrein
fig
fragment
contain
amino
acid
residu
g
exhibit
leukocytosislik
properti
possibl
link
intriguingli
anoth
member
kallikrein
klk
serin
proteas
famili
prostatespecif
antigen
psa
shown
digest
purifi
addit
cleavag
occur
chymotrypsinlik
cleavag
site
without
aid
factor
h
give
rise
novel
fragment
origin
portion
fig
pattern
cleavag
also
seen
prostat
fluid
semin
plasma
present
addit
report
cleav
therebi
gener
function
activ
without
downstream
gener
trypsin
chymotrypsin
elastas
broad
specif
cleav
whole
nativ
molecul
small
proteolyt
fragment
dosedepend
manner
basic
cleavag
region
physiolog
cleavag
potenti
gener
proteolyt
fragment
biolog
activ
instanc
low
concentr
trypsin
gener
facilit
cleavag
g
elastas
report
promot
similar
digest
schemat
overview
proteolyt
digest
result
fragment
present
fig
physiolog
cleavag
homolog
much
less
well
understood
probabl
complex
cleav
convertas
gener
classicallectin
altern
pathway
addit
number
studi
shown
noncompl
proteas
particularli
proteas
coagul
cascad
eg
thrombin
fxa
plasmin
abl
cleav
nativ
also
discuss
find
contradict
studi
exampl
thrombin
report
gener
form
cleav
correspond
third
bfactor
cleavag
siteand
convertas
site
gener
form
design
still
abl
support
format
termin
pathway
complex
form
also
gener
nativ
expos
trypsin
low
concentr
prof
ulf
nilsson
person
commun
plasmin
fxa
proteas
like
cleav
convertas
site
reason
concentr
gener
discrep
studi
may
explain
find
crystal
structur
resolut
unlik
cleavag
site
convertas
hidden
nativ
molecul
necessit
conform
chang
molecul
site
becom
access
mechan
induc
conform
chang
known
probabl
key
understand
function
abovement
proteas
convertas
addit
proteas
activ
coagul
factor
shown
gener
therebi
also
complement
activ
trigger
fxa
rel
low
concentr
ad
serum
tabl
activ
result
gener
decreas
hemolyt
activ
increas
anaphylact
activ
complementactiv
activ
block
anticoagul
eg
fondaparinux
studi
show
coagul
factor
activ
complement
complex
serum
milieu
howev
like
activ
would
lower
plasma
contain
intact
nativ
coagul
factor
prefer
substrat
mani
experi
purifi
compon
concentr
proteas
ad
close
theoret
limit
ie
total
amount
fig
cleavag
complement
noncompl
proteas
summari
cleavag
b
local
report
cleavag
site
three
region
top
lead
gener
activ
convertas
classic
lectin
pathway
andor
altern
pathway
subsequ
cleav
factor
togeth
cofactor
g
smaller
fragment
similar
cleavag
also
accomplish
proteas
like
trypsin
chymotrypsin
elastas
addit
report
cleav
psa
kallikrein
cleav
ctermin
end
carboxypeptidas
gener
desarg
ap
altern
pathway
cp
classic
pathway
lp
lectin
pathway
psa
prostatespecif
antigen
fh
factor
h
mcp
membran
cofactor
protein
complement
psa
prostatespecif
antigen
klk
kallikrein
carboxypeptidas
tafi
thrombinactivat
fibrinolysi
inhibitor
zymogen
convert
activ
enzym
addit
studi
proteas
test
one
time
question
possibl
synergist
effect
address
howev
sever
situat
clinic
set
condit
approach
instanc
dissemin
intravascular
coagulopathi
dic
sepsi
system
exhaust
intravascular
proteas
inhibitor
consum
eg
furthermor
dysregul
circumst
small
amount
activ
gener
coagul
proteas
alon
combin
may
suffici
initi
fullblown
inflamm
result
amplif
altern
pathway
complement
number
human
pathogen
eg
borrelia
streptoccocu
leptospira
interrogan
acquir
plasminogen
surfac
use
proteolyt
activ
plasmin
cleav
inactiv
order
disarm
host
immun
defens
see
eg
refer
therein
cleav
ctermin
end
carboxypeptidas
gener
desarg
desarg
fragment
lower
affin
receptor
therefor
consid
inactiv
form
anaphylatoxin
although
total
without
effect
activ
carboxypeptidas
carboxypeptidas
n
carboxypeptidas
latter
activ
deriv
procarboxypeptidas
r
thrombinactivat
fibrinolysi
inactiv
tafi
coagulationfibrinolyt
cascad
illustr
linkag
coagul
complement
system
proteolyt
digest
featur
activ
sever
report
suggest
may
cleav
proteas
belong
complement
system
human
shown
sensit
digest
trypsin
chymotrypsin
pepsin
collagenas
contrast
trypsin
chymotrypsin
collagenas
treatment
lead
product
welldefin
fragment
show
moder
decreas
bind
immun
complex
compar
intact
clinic
set
acut
pancreat
develop
abscess
inflamedinfect
tissu
may
decompos
result
uncontrol
activ
proteas
moreov
system
inflammatori
condit
proteas
seem
act
major
driver
pathophysiolog
inflamm
organ
dysfunct
exampl
sepsi
defin
system
inflammatori
respons
syndrom
sir
presenc
pathogen
enhanc
level
trypsin
elastas
metalloproteinas
well
mani
enzym
detect
held
respons
gener
inflammatori
respons
noteworthi
releas
proteas
origin
host
andor
invad
microorgan
contain
enzym
similar
divers
function
exampl
case
lyell
syndrom
manifest
acut
lifethreaten
epidermolysi
two
differ
form
exist
one
steril
druginduc
toxic
epiderm
necrolysi
ten
host
proteas
respons
detach
epidermi
dermi
drug
administr
make
entir
bodi
suscept
subsequ
infecti
invas
complic
form
known
staphylococc
scald
skin
syndrom
ssss
induc
serin
proteas
exfoliatin
releas
invad
staphylococcu
aureu
final
result
highli
specif
breakdown
desmosom
diseas
associ
complex
system
reaction
hemorrhag
shock
hs
acut
kidney
injuri
aki
adult
respiratori
distress
syndrom
ard
proteas
function
import
inflammatori
trailblaz
excess
system
activ
proteas
may
even
result
propos
bautodigestionphenomenon
may
clinic
crucial
develop
multipleorgan
dysfunct
syndrom
mod
often
fatal
multipl
organ
failur
mof
case
multipl
trauma
polytrauma
proteas
releas
activ
describ
may
also
respons
system
activ
deplet
coagul
system
manifest
acut
traumainduc
coagulopathi
hand
intens
crosstalk
complement
coagul
cascad
accompani
platelet
activ
variou
proteas
inhibitor
critic
involv
thrombu
format
taken
togeth
find
indic
mani
acut
diseas
proteas
act
local
system
groundbreak
tissu
invas
pathogenassoci
molecul
pamp
immun
cell
gener
classic
sign
inflamm
btumor
rubor
dolor
calor
function
laesa
easili
affect
whole
bodi
therefor
specif
therapeut
target
proteas
beyond
complement
coagul
cascad
repres
promis
subject
research
clinic
investig
futur
overview
differ
clinic
set
enabl
massiv
releas
proteolyt
enzym
found
fig
acut
lifethreaten
epidermolysi
sever
decad
ago
complement
coagul
system
propos
import
actor
develop
ten
lyell
syndrom
caus
proteolyt
shed
epidermi
respons
certain
drug
occasion
microorgan
stevensjohnsonsyndrom
sj
ten
differ
degre
epiderm
detach
affect
bodi
surfac
area
case
sj
ten
sjsten
overlap
pathophysiolog
diseas
repres
sever
hypersensit
reaction
activ
cytotox
lymphocyt
natur
killer
cell
cell
turn
mediat
immun
reaction
direct
keratinocyt
furthermor
immun
reaction
associ
releas
cytokin
perforin
granzym
b
sever
proteas
final
result
keratinocyt
death
disintegr
epidermi
although
yet
implic
lifethreaten
skin
diseas
serin
proteas
granzym
b
shown
directli
activ
complement
noncanon
manner
gener
anaphylatoxin
induc
cardin
sign
inflamm
given
rariti
diseas
random
clinic
trial
sj
ten
howev
clinic
case
report
trypsin
inhibit
ulinastatin
benefici
relat
diseas
ssss
caus
pamp
toxin
proteas
staphylococcu
aureu
seem
critic
involv
complement
activ
dysregul
staphylococcu
toxin
activ
complement
coagul
also
evad
complement
surveil
exampl
staphylococc
complement
inhibitor
scin
effect
stabil
convertas
nonfunct
state
allow
escap
complement
attack
exfoli
toxin
aureu
serin
proteas
cleav
desmoglein
import
compon
structur
integr
epidermi
whether
toxin
also
cleav
activ
deactiv
complement
coagul
factor
remain
clarifi
sever
tissu
injuri
rapid
activ
complement
coagul
cascad
report
potenti
develop
harm
traumainduc
coagulopathi
complementopathi
although
import
crosstalk
two
cascad
postul
clinic
studi
assess
direct
impact
import
traumat
critic
ill
patient
one
studi
analyz
septic
patient
compar
multipleinjuri
patient
found
enhanc
plasma
level
leukocyt
reduc
plasma
fibrinogen
platelet
count
remark
addit
increas
mof
score
lactat
concentr
reduc
activ
reliabl
predictor
poor
outcom
result
emphas
import
crossregulatori
driver
sinc
block
activ
complement
coagul
also
activ
contact
system
tempt
specul
polytrauma
extens
tissu
damag
ischem
stress
acidosi
hypothermia
reactiv
oxygen
radic
may
local
gener
complement
coagul
activ
product
attempt
control
bleed
inflamm
furthermor
system
activ
proteas
system
beyond
complement
coagul
cascad
may
result
bproteolyt
chao
turn
non
specif
cleav
activ
complement
coagul
factor
still
unknown
whether
cleavag
product
appear
nativ
protein
establish
structurefunct
relationship
exhibit
novel
function
extens
enhanc
activ
factor
viiactiv
proteas
fsap
repres
ancient
coagul
factor
found
associ
increas
plasma
level
anaphylatoxin
earli
polytrauma
vitro
exposur
fsap
key
complement
compon
reveal
abil
cleav
fragment
howev
lack
four
amino
acid
n
terminu
interestingli
without
alter
molecul
function
profil
fsapinduc
cleavag
result
two
differ
size
cleavag
product
whose
exact
function
vitro
clinic
set
still
unknown
clinic
trauma
thorax
enhanc
level
found
bronchoalveolar
lavag
bal
fluid
depend
volum
contus
lung
tissu
subsequ
develop
pneumonia
studi
author
show
enhanc
level
bal
fluid
trauma
retransl
approach
employ
rodent
thorax
trauma
model
interestingli
blockad
thrombin
potent
serin
proteas
hirudin
reduc
thrombin
level
also
significantli
reduc
concentr
point
thrombininduc
complement
activ
major
contributor
acut
lung
injuri
blunt
chest
trauma
similarli
plasma
concentr
serin
proteas
granzym
b
shown
group
increas
earli
stage
multipl
injuri
human
abl
gener
anaphylatoxin
vitro
moreov
granzym
b
also
shown
cleav
von
willebrand
factor
vwf
matrix
form
fibrinogen
sever
site
result
overal
anticoagulatori
activ
proteas
speci
seem
gener
rapidli
sever
tissu
trauma
exampl
aspartylproteas
cathepsin
significantli
increas
plasma
patient
earli
polytrauma
may
gener
protein
although
cleavag
classic
serin
moieti
rather
unlik
exact
origin
mechan
proteas
activ
sever
tissu
trauma
well
defin
nevertheless
somehow
surpris
proteas
inhibitor
effect
address
proteaseinduc
host
damag
also
control
coagul
complement
system
test
experiment
clinic
trauma
set
previou
experiment
report
traumahemorrhag
shock
describ
improv
surviv
rate
elastas
inhibitor
appli
result
reduct
cardiodepress
factor
similarli
traumat
spinal
cord
injuri
model
elastas
inhibitor
show
promis
result
block
sensor
system
nitric
oxid
promot
function
recoveri
reduc
inflammatori
respons
howev
noth
report
complement
clot
effect
particular
valid
translat
data
avail
case
trypsin
inhibitor
ulinastatin
small
studi
traumahemorrhag
shock
patient
perform
reveal
modest
earli
effect
reduct
serum
neutrophilderiv
elastas
within
h
effect
clinic
relev
paramet
score
recent
clinic
studi
complex
set
polytrauma
ukg
infus
min
start
femor
pelvic
fixat
oper
termin
final
result
yet
publish
welldevelop
wellevalu
proteas
inhibitor
clinic
aprotinin
inhibit
serin
proteas
metaanalysi
examin
orthoped
surgeri
associ
signific
tissu
trauma
indic
benefit
serin
proteas
blockad
reduc
blood
loss
need
transfus
enhanc
risk
thromboembol
event
report
pig
model
hemorrhag
shock
indic
local
applic
synthet
serin
proteas
inhibitor
nafamostat
produc
improv
clinic
outcom
paramet
howev
reliabl
data
avail
serin
proteas
inhibitori
strategi
complex
polytrauma
condit
taken
togeth
data
indic
although
evid
bproteas
stormaft
sever
tissu
trauma
inhibit
specif
proteas
traumahemorrhag
situat
seem
limit
help
complex
clinic
set
approach
may
even
disturb
acut
traumainduc
coagulopathi
thu
experiment
pathophysiolog
investig
certainli
warrant
human
sepsi
defin
infecti
wholebodi
inflamm
establish
induct
progress
system
respons
massiv
activ
complement
system
coagul
cascad
activ
may
result
immun
dysfunct
complementopathi
coagulopathi
multipl
organ
dysfunct
import
complementcoagul
interplay
pathophysiolog
develop
sepsi
demonstr
nonhuman
primat
particular
system
deplet
found
associ
develop
coagulopathi
elev
ddimer
infecti
complic
poor
prognosi
septic
patient
progress
sepsi
uncontrol
system
proteas
activ
report
enhanc
serum
concentr
trypsin
elastas
serin
proteas
activ
eg
fsap
bglobal
proteas
activationm
ay
mainli
respons
impair
inhibit
endogen
proteas
eg
drop
plasma
concentr
accordingli
substitut
sever
sepsi
human
shown
reduc
concentr
serum
surrog
paramet
also
reduc
overal
mortal
interestingli
human
antithrombin
act
specif
proteas
inhibitor
found
display
antimicrobi
activ
might
prove
support
sepsi
therapi
furthermor
septic
trauma
patient
enhanc
elastas
level
seem
contribut
significantli
tissu
factor
tf
tf
pathway
inhibitor
tfpi
imbal
turn
aggrav
ard
develop
sustain
system
inflamm
note
administ
patient
abdomin
sepsi
ard
select
neutrophil
elastas
inhibitor
sivelestat
result
earli
improv
oxygen
ventil
wean
well
improv
multipl
organ
function
context
experiment
data
shown
specif
elastas
inhibit
significantli
attenu
endotoxininduc
septic
acut
lung
injuri
also
reduc
concentr
alveolar
space
rodent
sepsisinduc
procoagulatori
activ
synchron
sign
dic
indic
prolong
activ
partial
thromboplastin
time
aptt
reduc
platelet
count
thrombinantithrombin
tat
complex
ddimer
tissueplasminogen
activ
tpa
mostli
revers
blockad
result
improv
surviv
rate
studi
illustr
clinic
potenc
crosstalk
serin
proteas
system
therefor
surpris
multipl
serin
proteas
inhibitori
strategi
clinic
appli
past
albeit
predominantli
sepsi
small
retrospect
singlecent
studi
investig
patient
sepsisinduc
dic
gabex
mesil
serin
proteas
inhibitor
versu
recombin
thrombomodulin
thrombomodulin
found
effect
improv
platelet
count
creactiv
protein
crp
concentr
mof
time
ulinastatin
multifunct
serin
proteas
inhibitor
propos
ban
excit
candidatefor
sepsi
therapi
recent
metaanalys
state
ulinastatin
alon
combin
thymosin
inde
result
improv
overal
surviv
reduc
gener
inflammatori
mediat
shorten
need
mechan
ventil
illumin
studi
human
admit
intens
care
unit
sir
reveal
approxim
protein
map
either
coagul
complement
system
differ
express
patient
develop
sepsi
versu
nonsept
sir
strikingli
differ
complement
coagul
protein
sir
patient
capabl
predict
septic
cours
even
h
sepsi
becam
clinic
evid
moreov
h
sepsi
onset
plasma
level
variou
endogen
proteas
inhibitor
decreas
suggest
specif
proteas
inhibitor
applic
might
serv
reason
therapeut
strategi
amelior
inhibit
sepsi
develop
howev
clinic
studi
need
precis
defin
appropri
indic
time
dosag
proteas
inhibitor
coagulatori
inflammatori
disord
sepsi
multipleorgan
dysfunct
syndrom
mod
may
consid
final
pathophysiolog
escal
rout
variou
diseas
polytrauma
sever
infect
sepsi
hematooncolog
diseas
mod
defin
signific
increment
function
derang
least
two
organ
still
associ
high
mortal
rate
interestingli
mod
major
function
defect
necessarili
reflect
major
morpholog
defect
even
though
multipl
function
crosstalk
organ
system
liverkidney
lungkidney
braingut
axe
involv
complex
organ
respons
case
sever
ard
clinic
proteom
analysi
reveal
proteaseantiproteas
imbal
significantli
enhanc
truncat
form
also
associ
complement
activ
increas
level
indic
tightli
interact
pulmonari
proteaseinflamm
respons
context
surpris
also
case
ard
recent
metaanalysi
clinic
studi
point
benefici
effect
block
trypsin
use
ulinastatin
although
data
complement
coagul
miss
last
two
decad
crosstalk
complement
coagul
cascad
also
describ
involv
trigger
promot
develop
mod
consequ
blockad
cecal
ligat
punctureinduc
sepsi
subsequ
mod
prove
protect
regard
coagulatori
respons
also
organ
perform
ie
improv
oxygen
lung
reduct
lactat
gener
amelior
acut
liver
kidney
injuri
nonhuman
primat
model
e
coliinduc
mod
blockad
complement
factor
inhibitor
compstatin
inhibit
central
complement
activ
also
reduc
sign
coagulopathi
reduc
tf
plasminogen
activ
fibrinogen
fibrindegrad
product
aptt
maintain
anticoagulatori
properti
endothelium
furthermor
compstatin
improv
hemodynam
concurr
liver
kidney
function
evid
fewer
microvascular
thrombi
improv
vascular
barrier
function
clinic
set
integr
clinicotranscriptom
approach
recent
correl
earli
thrombocytopenia
mod
develop
express
level
nosocomi
infect
regard
therapeut
inhibit
noncanon
crosstalk
proteas
system
trypsin
inhibitor
ulinastatin
found
exert
protect
effect
immun
respons
hemostasi
similarli
vitro
thrombelastometr
analys
indic
anticoagulatori
effect
translat
studi
abdomin
surgeri
shown
evid
antiinflammatori
effect
via
inhibit
neutrophil
elastas
activ
also
anticoagulatori
antifibrinolyt
effect
via
reduct
level
tat
complex
inhibitorcomplex
pic
fibrin
fibrinogen
degrad
product
anoth
studi
sever
sepsi
patient
ulinastatin
impress
reduc
incid
mod
onset
furthermor
anoth
serin
proteas
inhibitor
gabex
mesil
shown
promis
result
rodent
endotoxininduc
mod
model
shortterm
pretreat
result
improv
lung
liver
kidney
function
reduct
consumpt
coagulopathi
determin
thrombelastographi
inflammatori
respons
reduct
tat
gener
temporari
artifici
organ
replac
assist
devic
bridg
function
organ
derang
fullblown
mod
may
activ
complement
coagul
system
shown
case
extracorpor
liverassist
devic
lungassist
devic
latest
improv
extracorpor
oxygen
system
still
exhibit
tendenc
consumpt
tat
complex
format
run
time
hand
surfac
coat
extracorpor
membran
oxygen
devic
nafamostat
mesil
recent
led
increas
bleed
risk
compar
standard
heparin
use
thu
molecular
surfac
engin
requir
futur
organ
assist
system
artifici
surfac
order
prevent
crossactiv
complement
clot
cascad
furthermor
bedsid
monitor
proteas
activ
includ
complement
coagul
system
desir
specif
target
stop
viciou
cycl
proteas
activ
subsequ
immun
coagul
organ
failur
although
role
clot
cascad
develop
acut
pancreat
well
establish
function
complement
process
like
crosstalk
system
trigger
massiv
proteas
releas
remain
unclear
indic
recent
review
acut
pancreat
enhanc
plasma
level
termin
complement
complex
found
human
correl
sever
diseas
nevertheless
case
acut
pancreat
pancreasderiv
proteas
trypsin
propos
function
culprit
mod
develop
support
data
come
metaanalysi
show
ulinastatin
improv
indic
inflamm
acut
pancreat
anoth
metaanalysi
shown
nafamostat
strong
coagul
complement
inhibitori
profil
effect
postendoscop
retrograd
cholangiopancreatographi
ercp
induc
pancreat
past
experiment
data
acut
hemorrhag
pancreat
sheep
indic
serin
proteas
inhibitor
aprotinin
significantli
reduc
pathophysiolog
consequ
crosstalk
system
dic
granulocyt
sequestr
remot
lung
vascular
permeabl
howev
translat
studi
reveal
less
convinc
result
therefor
applic
aprotinin
abandon
treatment
pancreat
especi
sinc
hyperfibrinolyt
state
pancreat
major
target
aprotinin
therapi
could
monitor
reliabl
prethrombelastographi
era
current
aprotinin
administr
mainli
restrict
complex
cardiac
surgeri
see
major
orthoped
surgeri
shown
reduc
transfus
requir
without
increas
risk
thrombosi
although
mechanist
ration
proteas
inhibit
pancreat
improv
clot
inflammatori
complic
would
benefit
greatli
proteas
monitor
yet
horizon
major
cardiac
surgeri
known
induc
certain
degre
system
inflamm
crossactiv
coagul
complement
system
particularli
onpump
condit
activ
kallikreinkininsystem
bradykinin
factor
xiia
tpa
cardiopulmonari
bypass
cpb
surgeri
along
enhanc
level
system
inflammatori
cytokin
tnf
well
establish
simul
extracorpor
circul
experi
suggest
contact
complement
system
activ
evidenc
format
complex
well
neutrophil
elastas
gener
inhibit
specif
kallikrein
blocker
howev
translat
clinic
inhibit
serin
proteas
kallikrein
achiev
exampl
administr
fulldos
aprotinin
thought
antifibrinolyt
antiinflammatori
characterist
therapeut
approach
around
cpb
oper
remain
question
given
data
singlecent
studi
also
metaanalys
sever
proteas
system
cathepsin
trypsin
report
activ
cpb
system
may
turn
directli
cleav
key
compon
complement
cascad
therefor
trypsin
inhibit
ulinastatin
origin
seem
ration
therapeut
approach
howev
base
recent
metaanalysi
random
clinic
trial
ulinastatin
fail
significantli
modul
cytokin
profil
reduc
durat
mechan
ventil
clinic
requir
contrast
anoth
metaanalysi
includ
cpb
patient
china
japan
indic
ulinastatin
decreas
need
mechan
ventil
also
improv
cytokin
profil
anoth
therapeut
strategi
inhibit
crosstalk
inflamm
coagul
address
potent
serin
proteas
fxiia
bridg
intrins
pathway
clot
system
classic
pathway
complement
system
inhibit
fxiia
antibodi
block
fxia
gener
format
activ
product
also
thrombin
fibrin
kallikrein
activ
conclus
seem
equal
potenc
anticoagulatori
effect
induc
heparin
therefor
suggest
safe
promis
altern
heparin
cpb
surgeri
critic
review
evid
base
differ
intervent
modul
unquestion
system
respons
cpb
suggest
blockad
sever
clinic
benefit
includ
myocardi
protect
pleiotrop
agent
target
coagul
complement
fibrinolyt
system
consid
ideal
bmultihitmodel
cpb
case
inhibit
monoclon
antibodi
pexelizumab
fail
significantli
improv
overal
surviv
cpb
patient
howev
confer
clear
surviv
benefit
highrisk
surgic
cpb
subgroup
throughout
observ
period
nevertheless
effect
inhibit
coagul
system
cpb
patient
document
need
futur
detail
consider
promis
therapeut
strategi
maintain
termin
complement
activ
pathway
reflect
current
phase
ii
studi
complex
cardiac
surgeri
use
monoclon
antibodi
target
peak
level
primari
endpoint
anoth
promis
approach
cpb
surgeri
modif
surfac
coat
bypass
circuit
one
studi
use
heparinco
closedcircuit
system
result
lower
concentr
tpa
neutrophil
elastas
rewarm
phase
overal
coat
strategi
seem
essenti
modul
system
inflammatori
respons
cpb
may
therefor
includ
complement
coagul
inhibit
classic
achiev
heparin
coat
specif
address
contact
system
seem
interest
clinic
goal
physiolog
condit
activ
cascad
system
strict
control
result
high
specif
gener
enzym
influenc
oblig
cofactor
limit
risk
crossactiv
system
howev
mani
clinic
set
featur
massiv
releas
proteolyt
enzym
auxiliari
function
allow
circumv
regul
enabl
uncontrol
complementcoagul
crosstalk
furthermor
presenc
enzym
seem
central
pathophysiolog
signific
sever
diseas
success
clinic
studi
research
effort
need
defin
critic
extent
proteas
activ
exact
mechan
respons
diseas
gener
deleteri
outcom
still
order
avoid
risk
advers
effect
associ
inhibit
central
compon
complement
coagul
cascad
specif
target
interfer
downstream
proteas
exert
de
facto
harm
function
may
prove
valuabl
tool
prevent
therapeut
strategi
